Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
elegans div-1 was first identified as a key regulator for asymmetric cell division by controlling the proper timing of early embryonic cell division (Encalada et al., 2000)
(2018) 20(Suppl 1):521
Work in Lausanne (BT) was supported by grants from the Swiss National Science Foundation and the European Research Council
US$ 24.84
US$ 24.84
US$ 25.90
/sc-assets/prd/practices/cdcd65da-a892-465a-aa2c-48d5c1f8134f/Tirzepatide%20vial.png)
US$ 23.05
